NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$485.53

+3.12 (+0.65%)

(As of 02/6/2023 12:00 AM ET)

Add

Compare

Today's Range: $462.60
▼
$497.85
50-Day Range: $399.93
▼
$504.22
52-Week Range: $317.06
▼
$560.92

Volume: 991,095 shs
Average Volume: 575,232 shs
Market Capitalization: $40.21 billion

P/E Ratio: 61.69
Dividend Yield: N/A
Price Target: $485.00

Institutional Ownership

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 0.1% Downside
$485.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -2.80
Upright™ Environmental Score
News Sentiment: 0.58
Based on 26 Articles This Week
Insider Trading: Selling Shares
$12.54 M Sold Last Quarter
Proj. Earnings Growth: 19.75%
From $7.90 to $9.46 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

528th out of 1,027 stocks

Diagnostic Substances Industry

9th out of 15 stocks

1.4

Analyst's Opinion

Consensus Rating
IDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $485.00, IDEXX Laboratories has a forecasted downside of 0.1% from its current price of $485.53.
Amount of Analyst Coverage
IDEXX Laboratories has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for IDXX.

0.0

Dividend Strength

Dividend Yield
IDEXX Laboratories does not currently pay a dividend.
Dividend Growth
IDEXX Laboratories does not have a long track record of dividend growth.

2.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEXX Laboratories has received a 20.02% net impact score from Upright. Idexx Laboratories seems to create the most significant positive value in categories "Taxes", "Nutrition", and "Jobs". The positive contribution in the "Nutrition" impact category is mostly driven by its "Veterinary x-rays", "Veterinary hematology analyzers", and "Veterinary services for livestock" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEXX Laboratories is -2.80.

3.1

News and Social Media Coverage

News Sentiment
IDEXX Laboratories has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 26 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.
Search Interest
20 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,541,681.00 in company stock.
Percentage Held by Insiders
Only 2.06% of the stock of IDEXX Laboratories is held by insiders.
Percentage Held by Institutions
87.90% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for IDEXX Laboratories are expected to grow by 19.75% in the coming year, from $7.90 to $9.46 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEXX Laboratories is 61.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.56.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEXX Laboratories is 61.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 141.66.
Price to Earnings Growth Ratio
IDEXX Laboratories has a PEG Ratio of 2.94. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
IDEXX Laboratories has a P/B Ratio of 59.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in West

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

February 7, 2023 | americanbankingnews.com

Research Analysts Set Expectations for IDEXX Laboratories, Inc.'s FY2023 Earnings (NASDAQ:IDXX)

February 6, 2023 | finance.yahoo.com

Analyst Says IDEXX Laboratories' Long-Term Growth Outlook Remains Strong

February 7, 2023 | Wall Street Watch Dogs (Ad)

A gold storm is coming…

“We are in the early stages of a mania – the calm before the storm.”...

February 6, 2023 | msn.com

IDEXX Laboratories Posts Better-Than-Expected Fourth-Quarter Results, Offers In-Line Full-Year 2023 Guidance

February 6, 2023 | finanznachrichten.de

IDEXX Laboratories, Inc.: IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results

February 6, 2023 | baystreet.ca

IDEXX Stumbles on Q4 and Full-Year Figures

February 6, 2023 | markets.businessinsider.com

IDEXX Laboratories Sees Higher Earnings, Revenues In FY23 - Update

February 6, 2023 | markets.businessinsider.com

IDEXX Laboratories Inc Q4 Income Climbs, Beats estimates

February 7, 2023 | Investing Trends (Ad)

Solar Industry at Start of Long Bull Run?

The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.

February 6, 2023 | finance.yahoo.com

IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results

February 6, 2023 | finance.yahoo.com

Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates

February 6, 2023 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Updates FY23 Earnings Guidance

February 5, 2023 | reuters.com

IDXX.OQ - | Stock Price & Latest News | Reuters

February 4, 2023 | finance.yahoo.com

Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?

February 4, 2023 | americanbankingnews.com

IDEXX Laboratories (IDXX) Set to Announce Quarterly Earnings on Monday

February 3, 2023 | msn.com

A Preview Of IDEXX Laboratories's Earnings

February 3, 2023 | seekingalpha.com

IDEXX Laboratories Q4 2022 Earnings Preview

January 31, 2023 | marketwatch.com

IDEXX Laboratories Inc. stock falls Tuesday, underperforms market

January 31, 2023 | finance.yahoo.com

SONVY or IDXX: Which Is the Better Value Stock Right Now?

January 29, 2023 | americanbankingnews.com

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $473.13 Average PT from Analysts

January 29, 2023 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $530.00 at The Goldman Sachs Group

January 26, 2023 | finance.yahoo.com

IDEXX Laboratories to Release 2022 Fourth Quarter and Full Year Financial Results

January 25, 2023 | finance.yahoo.com

Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

January 25, 2023 | finance.yahoo.com

IDEXX Laboratories Is Barking Up the Right Tree

January 24, 2023 | marketwatch.com

IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors

January 18, 2023 | finance.yahoo.com

Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago

January 12, 2023 | finance.yahoo.com

Does IDEXX Laboratories (NASDAQ:IDXX) Have A Healthy Balance Sheet?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings: 2/06/2023
Today: 2/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:IDXX
CUSIP: 45168D10
CIK: 874716
Web: www.idexx.com
Phone: (207) 556-0300
Fax: 207-556-4346
Employees: 10,350
Year Founded: 1983

Price Target and Rating

Average Stock Price Forecast: $485.00
High Stock Price Forecast: $582.00
Low Stock Price Forecast: $415.00
Forecasted Upside/Downside: -0.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $7.87
Trailing P/E Ratio: 61.69
Forward P/E Ratio: 61.46
P/E Growth: 2.94
Net Income: $744.84 million
Net Margins: 20.05%
Pretax Margin: 25.11%
Return on Equity: 118.38%
Return on Assets: 26.06%

Debt

Debt-to-Equity Ratio: 1.60
Current Ratio: 0.89
Quick Ratio: 0.59

Sales & Book Value

Annual Sales: $3.22 billion
Price / Sales: 12.51
Cash Flow: $10.08 per share
Price / Cash Flow: 48.16
Book Value: $8.14 per share
Price / Book: 59.65

Miscellaneous

Outstanding Shares: 82,820,000
Free Float: 81,111,000
Market Cap: $40.21 billion
Optionable: Optionable
Beta: 1.17

Social Links

Key Executives

Jonathan J. Mazelsky
President, Chief Executive Officer & Director

Brian Patrick McKeon
Chief Financial Officer, Treasurer & Executive VP

Ken Grady
Chief Information Officer & Senior VP

Murthy Yerramilli
Senior Vice President-Research & Development

Martin Alexander Smith
Chief Technology Officer & Executive VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.
What is IDEXX Laboratories' stock price forecast for 2023?: 8 analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they predict the company's share price to reach $485.00 in the next year. This suggests that the stock has a possible downside of 0.1%.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.
How have IDXX shares performed in 2023?: IDEXX Laboratories' stock was trading at $407.96 on January 1st, 2023. Since then, IDXX shares have increased by 19.0% and is now trading at $485.53.
View the best growth stocks for 2023 here.
When is IDEXX Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our IDXX earnings forecast.
How were IDEXX Laboratories' earnings last quarter?: IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Monday, February, 6th. The company reported $2.05 EPS for the quarter, topping analysts' consensus estimates of $1.92 by $0.13. The firm earned $828.60 million during the quarter, compared to analyst estimates of $820.91 million. IDEXX Laboratories had a net margin of 20.05% and a trailing twelve-month return on equity of 118.38%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the company posted $1.89 EPS.
What guidance has IDEXX Laboratories issued on next quarter's earnings?: IDEXX Laboratories updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share guidance of $9.27-$9.75 for the period, compared to the consensus EPS estimate of $9.50. The company issued revenue guidance of $3.59 billion-$3.69 billion, compared to the consensus revenue estimate of $3.62 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?: 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.
What other stocks do shareholders of IDEXX Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).
What is IDEXX Laboratories' stock symbol?: IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
Who are IDEXX Laboratories' major shareholders?: IDEXX Laboratories' stock is owned by many different retail and institutional investors. Top institutional investors include LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Manning & Napier Group LLC (0.21%), Welch & Forbes LLC (0.21%) and Bank Julius Baer & Co. Ltd Zurich (0.20%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.
How do I buy shares of IDEXX Laboratories?: Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IDEXX Laboratories' stock price today?: One share of IDXX stock can currently be purchased for approximately $485.53.
How much money does IDEXX Laboratories make?: IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $40.21 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.87 on an earnings per share basis.
How many employees does IDEXX Laboratories have?: The company employs 10,350 workers across the globe.
How can I contact IDEXX Laboratories?: IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 2/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IDEXX Laboratories - IDXX Stock Forecast, Price & News

IDEXX Laboratories MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDXX Stock News Headlines

IDXX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

IDXX Stock - Frequently Asked Questions

Overall MarketRank^™